期刊
JOURNAL OF HEPATOLOGY
卷 51, 期 3, 页码 468-474出版社
ELSEVIER
DOI: 10.1016/j.jhep.2009.05.031
关键词
Lamivudine; Portal pressure; Hepatitis B DNA; Prognosis
Background/Aims: Lamivudine improves liver histology in patients with chronic hepatitis B (CHB), but its effects on portal pressure remain unknown. We evaluated the effect of lamivudine monotherapy on hepatic venous pressure gradient (HVPG) in CHB-related cirrhosis with significant portal hypertension. Methods: We studied 19 patients with cirrhosis due to HBeAg-negative CHB and HVPG >= 10 mm Hg treated with oral lamivudine (100 mg daily). Liver biochemistry, Child-Pugh and MELD score were determined every 3 months, alpha-fetoprotein and HBV DNA every 6 months and HVPG at baseline and at 12 months after lamivudine initiation. Diuretics, beta-blockers, antibiotics and/or endoscopic therapy were used for routine indications. Results: At 12 months, a significant reduction was observed in ALT (p = 0.001), HBV DNA (p = 0.002), Child-Pugh (p = 0.012) and MELD score (p = 0.006). Four patients developed virological breakthrough during treatment. At 12 months, HVPG decreased in all but one patient [baseline: 14.4 +/- 3.9 and 12 months: 12.4 +/- 3.3 mm Hg (p = 0.007)]. HVPG decreased >20% or below the 12 mm Hg threshold in 10 of 13 patients with baseline HVPG >= 12 mm Hg. HVPG increased in a patient with hepatic flare after virological breakthrough. Conclusion: In conclusion, in patients with cirrhosis due to HBeAg-negative CHB, lamivudine monotherapy reduces HVPG, especially when virological suppression and biochemical remission is achieved. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据